Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 14/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12906161 | 0.68 | NOTUM (0.59) | NOTUMTSHRMAPTALDH1A1TLR8 | |
| SCHEMBL539177 | 0.64 | NOTUM (0.41) | NOTUMTSHRALDH1A1LMNAHPGD | |
| SCHEMBL22738890 | 0.63 | NOTUM (0.48) | NOTUMTSHRMAPTALDH1A1TLR8 | |
| SCHEMBL7255351 | 0.61 | NOTUM (0.38) | NOTUMTSHRMAPTALDH1A1TLR8 | |
| SCHEMBL28450882 | 0.61 | NOTUM (0.38) | NOTUMTSHRMAPTTLR8 | |
| SCHEMBL6050750 | 0.61 | KMT2A (0.39) | NOTUMMAPTALDH1A1LMNAHPGD | |
| SCHEMBL1932823 | 0.60 | GOT1 (0.31) | — | |
| SCHEMBL17694561 | 0.60 | NOTUM (0.78) | NOTUMTSHRMAPTALDH1A1TLR8 | |
| SCHEMBL4760927 | 0.59 | NOTUM (0.39) | NOTUMTSHRMAPTALDH1A1TLR8 | |
| SCHEMBL4476133 | 0.59 | NOTUM (0.48) | NOTUMTSHRMAPTALDH1A1TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237074-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC Foundation for Research Development (10 pp.) | 2016-08-18 | — | — | US | disclosed |
| US-20130137728-A1 | Compositions and Methods for the Treatment of Degenerative Diseases | MUSC Foundation for Research and Development (US) | 2013-05-30 | — | — | US | disclosed |
| EP-2550260-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEGENERATIVE DISEASES | Medical University Of South Carolina (US) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011119869-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEGENERATIVE DISEASES | MEDICAL UNIVERSITY OF SOUTH CAROLINA (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237074-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | PCSK9, ACHE, CLN6 | NOTUM 111/4885TSHR 3863/4885MAPT 140/4885 |
| US-20130137728-A1 | Compositions and Methods for the Treatment of Degenerative Diseases | REN, PCSK9, LIPA | NOTUM 149/4885TSHR 3145/4885MAPT 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.